ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 65.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,618 shares of the biopharmaceutical company’s stock after selling 80,007 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in ACADIA Pharmaceuticals were worth $764,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. SG Americas Securities LLC grew its position in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period. Barclays PLC raised its stake in shares of ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after acquiring an additional 154,854 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of ACADIA Pharmaceuticals in the third quarter valued at approximately $483,000. Burney Co. acquired a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $6,953,000. Finally, BNP Paribas Financial Markets increased its position in shares of ACADIA Pharmaceuticals by 259.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock valued at $3,439,000 after purchasing an additional 161,331 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $19.95 on Monday. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $26.56. The firm has a fifty day moving average price of $18.20 and a two-hundred day moving average price of $16.73. The firm has a market cap of $3.32 billion, a price-to-earnings ratio of 25.58 and a beta of 0.37.

Analyst Ratings Changes

ACAD has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Finally, StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.